Highest-materiality recent filing
CEL-SCI raises $2.5M in common stock offering for Multikine development
2.5M shares sold at $1.00/share, gross proceeds $2.5M; offering closed June 16, 2026.
CEL-SCI enters 50/50 revenue-sharing partnership with Amarox for Multikine in Saudi Arabia
50%/50% net revenue share for Multikine sales in Saudi Arabia; Amarox exclusive distributor upon SFDA approval.
CEL-SCI raises $7.2M in public offering of 6M shares at $1.20/share
Gross proceeds of $7.2 million from 6,000,000 shares at $1.20 per share.
CEL-SCI board revises Shareholder Rights Agreement on Nov 18, 2025
Board approved revisions to the Shareholder Rights Agreement effective November 18, 2025.
CEL-SCI extends shareholder rights plan expiration to October 30, 2030
Board amended the Shareholder Rights Agreement on October 30, 2025.
CEL-SCI closes $10M public offering of 1.1M shares at $9.00 each
Closed best-efforts offering of 1,111,200 common shares at $9.00 each; gross proceeds ~$10M.
Breakthrough Medicine Designation application filed with SFDA by Dallah Pharma for Multikine.
CEL-SCI closes $5.7M at-the-market offering of 1.5M shares at $3.82
Gross proceeds ~$5.73M before placement agent fees (7%) and up to $95K expenses.
CEL-SCI closes $5M public offering of 2M shares at $2.50/share for Multikine development
Gross proceeds $5M from 2M shares at $2.50; underwriting discount $0.175 per share.
CEL-SCI shareholders approve stock combination and 2025 equity plans at annual meeting
Three directors elected: Geert Kersten (21.6M for), Bruno Baillavoine (16.3M for), Robert Watson (16.7M for).
CEL-SCI prices $2.56M offering of 16M shares or pre-funded warrants at $0.16/share
Gross proceeds of $2.56M from sale of 4,012,500 shares and pre-funded warrants for 11,987,500 shares.
CEL-SCI closes $5M public offering of 16.1M shares at $0.31 for Multikine development
Gross proceeds ~$5M from 7.55M shares + 8.58M pre-funded warrants at $0.31/$0.3099.
CEL-SCI appoints Patricia Prichep as CFO and COO, effective Nov 13, 2024
Patricia B. Prichep, current SVP of Operations, assumes dual CFO and COO role.
CEL-SCI appoints Dr. Nabil Saba as lead for Phase III Multikine study in head and neck cancer
Dr. Saba will serve as global Phase III confirmatory trial lead and Study Steering Committee member for Multikine.
CEL-SCI reports Multikine 5-year survival 82.6% in target head & neck cancer subgroup; HR 0.27
Multikine showed 82.6% 5-year overall survival in target low-risk patients vs 47.3% for standard of care.
CEL-SCI closes $10.8M public offering of common stock and pre-funded warrants
Gross proceeds of $10,845,000 from offering of 10,845,000 shares/common stock or pre-funded warrants at $1.00/share.
Bias analysis found no confounding baseline parameters; treatment and control arms are balanced, no bias detected.
CEL-SCI presents Multikine data: 5yr survival 73% vs 45% control; risk of death halved
Multikine cut risk of death by 50% in low PD-L1 head and neck cancer patients: 73% survival vs 45% control at 5 years.
CEL-SCI appoints Mario Gobbo to Board of Directors effective April 19, 2024
Mario Gobbo appointed to CEL-SCI Board; will serve on audit, nominating & governance, and compensation committees.
Geert Kersten, Bruno Baillavoine, Robert Watson elected as directors with >12M votes each; ~12.8M broker non-votes.
CEL-SCI raises $7.75M in public offering of 3.875M shares at $2.00/share
Gross proceeds of $7.75M; underwriter discount of $0.14 per share.
Issued 2,490,000 shares at $2.00 per share to a single investor; gross proceeds ~$4.98M.
CEO Geert Kersten's employment extended to August 31, 2027.
Target population: low PD-L1 (<10%), N0, no extracapsular spread; covers ~145,000 patients/year worldwide.
CEL-SCI extends employment agreements of SVP Prichep and CSO Talor to Aug 2027
Patricia B. Prichep's employment agreement extended to August 31, 2027, terms unchanged.
CEL-SCI closes $5M public offering of 2.5M shares at $2.00/share
Closed underwritten public offering of 2,500,000 common shares at $2.00 per share on July 20, 2023.
CEL-SCI prices $5M public offering of 2.5M shares at $2.00/share
Gross proceeds of $5,000,000 from 2.5M shares at $2.00 per share; net proceeds ~$4.5M.
CEL-SCI reports positive FDA meeting for Multikine approval; Canada possible 2024
FDA acknowledged need for improved head/neck cancer treatments; CEL-SCI preparing further development plan.
Low PD-L1 subgroup (TPS<10) showed 20% absolute 5-year overall survival advantage for Multikine+SOC vs SOC alone (60% vs 40% alive).
CEL-SCI shareholders elect all directors, approve stock plans and auditor at annual meeting
All five director nominees elected: Geert Kersten, Peter Young, Bruno Baillavoine, Robert Watson, Gail Naughton.
CEL-SCI closes public offering of ~913K shares at $1.70, raising ~$1.39M net
Issued 794,117 shares plus full exercise of 119,117 over-allotment shares at $1.70/share.
Offering of 794,117 shares at $1.70 per share; gross proceeds ~$1.35M, net ~$1.12M after discounts and expenses.
CEL-SCI to pursue Health Canada's conditional approval pathway for Multikine in head & neck cancer
Health Canada advised CEL-SCI to request approval under Notice of Compliance with Conditions (NOC/c) policy for Multikine.
CEL-SCI Multikine Phase 3 shows 43% survival extension; BLA submission planned
Multikine extended overall survival by 43% (HR 0.70; 95% CI 0.49-1.00) vs SOC in 352 LR head & neck cancer patients.
Patricia B. Prichep, CEL-SCI’s current senior Vice President of Operations, has assumed the duties of CEL-SCI’s Chief Financial and Operations Officer, effective November 13, 2024.
On April 19, 2024, CEL-SCI Corporation appointed Mario Gobbo to its Board of Directors.
Max materiality 0.85 · Median 0.60 · Most common event other_material